Vitamin D + Sham Exercise + Vitamin D + Exercise
Phase 1Terminated 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Elderly, Frail
Conditions
Elderly, Frail
Trial Timeline
Oct 1, 2005 → Jan 1, 2008
NCT ID
NCT00249704About Vitamin D + Sham Exercise + Vitamin D + Exercise
Vitamin D + Sham Exercise + Vitamin D + Exercise is a phase 1 stage product being developed by Pfizer for Elderly, Frail. The current trial status is terminated. This product is registered under clinical trial identifier NCT00249704. Target conditions include Elderly, Frail.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00249704 | Phase 1 | Terminated |
Competing Products
15 competing products in Elderly, Frail
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| YM150 + Placebo | Astellas Pharma | Phase 1 | 33 |
| ASP3325 + Placebo | Astellas Pharma | Phase 1 | 33 |
| E2022 Tape Formulation | Eisai | Phase 1 | 33 |
| Donepezil | Eisai | Approved | 85 |
| AZD3293 + Placebo | AstraZeneca | Phase 1 | 33 |
| TC-5214 + Placebo | AstraZeneca | Phase 1 | 33 |
| AZD3293 + Placebo | AstraZeneca | Phase 1 | 33 |
| Esmirtazapine | Merck | Phase 3 | 77 |
| Pertuzumab + trastuzumab + Pertuzumab + trastuzumab + metronomic chemotherapy | Roche | Phase 2 | 52 |
| PF-06648671 + Midazolam + Placebo | Pfizer | Phase 1 | 32 |
| PF-06743649 + Placebo + PF-06743649 + Placebo + PF-06743649 + Placebo + PF-06743649 + Placebo + PF-06743649 + Placebo | Pfizer | Phase 1 | 32 |
| HSK3486 + HSK3486 + HSK3486 + HSK3486 | Haisco Pharmaceutical Group | Phase 1 | 30 |
| Padsevonil | UCB | Phase 1 | 30 |
| TD-1439 + Placebo | Theravance Biopharma | Phase 1 | 28 |
| TD-0714 + Placebo | Theravance Biopharma | Phase 1 | 28 |